X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA DIVIS LABORATORIES AJANTA PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 19.7 34.4 57.3% View Chart
P/BV x 4.6 6.7 68.3% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 AJANTA PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
DIVIS LABORATORIES
Mar-18
AJANTA PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,8181,142 159.2%   
Low Rs1,106533 207.5%   
Sales per share (Unadj.) Rs239.5146.6 163.4%  
Earnings per share (Unadj.) Rs52.833.0 159.8%  
Cash flow per share (Unadj.) Rs59.538.4 154.9%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.2 0.0%  
Book value per share (Unadj.) Rs230.0222.8 103.2%  
Shares outstanding (eoy) m88.77265.47 33.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.15.7 106.9%   
Avg P/E ratio x27.725.3 109.2%  
P/CF ratio (eoy) x24.621.8 112.7%  
Price / Book Value ratio x6.43.8 169.2%  
Dividend payout %030.3 0.0%   
Avg Mkt Cap Rs m129,782222,318 58.4%   
No. of employees `0006.810.8 63.1%   
Total wages/salary Rs m3,7654,561 82.5%   
Avg. sales/employee Rs Th3,128.43,616.0 86.5%   
Avg. wages/employee Rs Th554.0423.8 130.7%   
Avg. net profit/employee Rs Th689.7814.9 84.6%   
INCOME DATA
Net Sales Rs m21,25838,915 54.6%  
Other income Rs m2421,134 21.3%   
Total revenues Rs m21,49940,049 53.7%   
Gross profit Rs m6,58412,617 52.2%  
Depreciation Rs m5961,425 41.8%   
Interest Rs m413 30.8%   
Profit before tax Rs m6,22612,313 50.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5393,543 43.4%   
Profit after tax Rs m4,6868,770 53.4%  
Gross profit margin %31.032.4 95.5%  
Effective tax rate %24.728.8 85.9%   
Net profit margin %22.022.5 97.8%  
BALANCE SHEET DATA
Current assets Rs m12,23645,351 27.0%   
Current liabilities Rs m3,4616,507 53.2%   
Net working cap to sales %41.399.8 41.4%  
Current ratio x3.57.0 50.7%  
Inventory Days Days60127 47.5%  
Debtors Days Days8495 88.8%  
Net fixed assets Rs m11,14021,160 52.6%   
Share capital Rs m177531 33.3%   
"Free" reserves Rs m20,23758,625 34.5%   
Net worth Rs m20,41459,156 34.5%   
Long term debt Rs m100-   
Total assets Rs m24,48667,832 36.1%  
Interest coverage x1,519.4926.8 163.9%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.6 151.3%   
Return on assets %19.212.9 147.9%  
Return on equity %23.014.8 154.8%  
Return on capital %30.520.8 146.4%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m11,66732,359 36.1%   
Fx outflow Rs m1,6169,042 17.9%   
Net fx Rs m10,05223,317 43.1%   
CASH FLOW
From Operations Rs m2,8547,759 36.8%  
From Investments Rs m-2,604-4,783 54.4%  
From Financial Activity Rs m-2-3,142 0.1%  
Net Cashflow Rs m248-166 -149.5%  

Share Holding

Indian Promoters % 73.8 52.0 141.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 11.8 13.1%  
FIIs % 7.6 19.0 40.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 17.2 98.8%  
Shareholders   20,968 31,796 65.9%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Recover; Healthcare & IT Stocks Witness Buying(12:30 pm)

Share markets in India have trimmed their early losses and are presently trading marginally lower. Sectoral indices are trading mixed with stocks.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Dec 11, 2018 01:01 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS